| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2007-11-20 |
| タイトル |
|
|
タイトル |
Metabolic monitoring of advanced uterine cervical cancer neoadjuvant chemotherapy by using [F-18]-Fluorodeoxyglucose positron emission tomography: preliminary results in three patients |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
FDG-PET for monitoring treatment response |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
Cervical cancer |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_1843 |
|
資源タイプ |
other |
| 著者 |
YOSHIDA, Yoshio
KUROKAWA, Tetsuji
KAWAHARA, Kazumi
YAGIHARA, Akira
TSUCHIDA, Tatsuro
OKAZAWA, Hidehiko
FUJIBAYASHI, Yasuhisa
YONEKURA, Yoshiharu
KOTSUJI, Fumikazu
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
[Objective] The aim of this report is to describe the potential clinical utility of tracer [F-18]-Fluorodeoxyglucose (FDG) uptake, quantitated as a standardized uptake value (SUV) by positron emission tomography (PET), to evaluate treatment response to neoadjuvant chemotherapy (NAC) in advanced uterine cervical cancer. [Methods] We briefly describe the clinical courses of three women with advanced cervical cancer who were treated with neoadjuvant chemotherapy (NAC) prior to radical hysterectomy and who were analyzed for correlation with the decrease in tumor volume by magnetic resonance imaging (MRI), in SUV by FDG-PET, and by histologic response. [Results] In these individuals, tumor volume and SUV were decreased by NAC. The decrease in SUV by FDG-PET was better correlated to histologic response for NAC than MRI was in advanced cervical cancer. [Conclusions] Measurement of SUV by FDG-PET has clinical utility in evaluating treatment response for NAC in advanced cervical cancer. Although work in this field is still in the early stages, this report demonstrates that SUV by FDG-PET has the potential to become the new standard for monitoring the treatment response of NAC in cervical cancer. This monitoring approach must be proven in a larger number of patients for both primary and secondary lesions and should be further explored in another gynecologic cancer. |
| 書誌情報 |
Gynecologic Oncology
巻 95,
号 3,
p. 597-602,
発行日 2004-12
|
| 出版者 |
|
|
出版者 |
Elsevier Ltd |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
908258 |
| 書誌レコードID |
|
|
|
識別子タイプ |
NCID |
|
|
関連識別子 |
TD00006286 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1016/j.ygyno.2004.08.037 |
| 著者版フラグ |
|
|
出版タイプ |
AO |
|
出版タイプResource |
http://purl.org/coar/version/c_b1a7d7d4d402bcce |
DOC071120.pdf (1.6 MB)
